Suzetrigine (Journavx): The First Non-Opioid Painkiller of a New Class in Decades
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Suzetrigine (Journavx): The First Non-Opioid Painkiller of a New Class in Decades

Suzetrigine blocks the NaV1.8 sodium channel in peripheral nerves and stops the pain signal from reaching the brain. In two phase 3 trials (1,118 and 1,073 participants) it significantly beat placebo for pain after surgery. How it is taken, who should see a doctor first and what has not yet been studied — from verified sources.

Suzetrigine (Journavx): The First Non-Opioid Painkiller of a New Class in Decades
For the first time in decades a painkiller has arrived with a genuinely new mechanism: it switches off a sodium channel in peripheral nerves, and the pain signal never reaches the brain. In two phase 3 trials after surgery it significantly beat placebo. Here is which pain it has been studied in, how it is taken, who should see a doctor first, and what remains open — from addiction to endometriosis.

Key points

Suzetrigine (Journavx) is the first painkiller of a new class in decades: it blocks the NaV1.8 sodium channel in peripheral nerves, and the pain signal does not reach the brain.

SituationHow it helpsWhat human studies showed
Moderate to severe acute pain in adultsthe main indication: approved by the FDA on 30 January 2025 as a new molecular entity; since January 2026 the label names postoperative pain explicitlytwo phase 3 trials: significantly better than placebo in both (Bertoch T, Anesthesiology 2025)
Pain after abdominoplastyrelieves pain in the first 48 hours after surgery1,118 participants: pain relief versus placebo 48.4 (CI 33.6–63.1), p < 0.0001; meaningful relief at 119 min vs 480 on placebo
Pain after bunion surgery on the footrelieves pain in the first 48 hours after surgery1,073 participants: pain relief versus placebo 29.3 (CI 14.0–44.6), p = 0.0002; meaningful relief at 240 min vs 480
Painful diabetic neuropathyunder study: three phase 3 trials are running, one phase 2 trial is complete—
Painful lumbosacral radiculopathy, small fibre diseaseunder study: there are research programmes—

How it helps

For decades pain relief has rested on two pillars: non-steroidal anti-inflammatories, which suppress inflammation, and opioids, which act in the brain. The first have a ceiling of effect and their own price for stomach and kidneys; the second bring sedation, tolerance and dependence — the dependence that cost the United States an epidemic.

Suzetrigine is built differently. It selectively blocks the NaV1.8 sodium channel — that one out of the nine known voltage-gated sodium channels. The channel operates in peripheral sensory neurons, including dorsal root ganglion neurons, and transmits pain signals. The label describes the result this way: by inhibiting NaV1.8, the drug inhibits transmission of pain signals to the spinal cord and brain. The signal is damped where it arises, not where it is perceived.

Hence the central promise: relief without reinforcement, and therefore without addiction. This is an expectation from the mechanism, and a logical one: the drug does not act in the brain, so it has nothing to reinforce behaviour with.

What the trials showed

Approval rested on two phase 3 trials, published together (Bertoch T, Anesthesiology 2025). Both models are elective surgery with predictably severe pain afterwards: NAVIGATE 2, abdominoplasty, and NAVIGATE 1, bunion surgery on the foot.

Follow-up ran 48 hours. The comparison was against two things at once: placebo, and a live competitor — the hydrocodone/acetaminophen combination, that is, an opioid.

The headline result: the drug works, and against placebo that is shown convincingly in both operations (the figures are in the table above). The authors describe pain reduction with suzetrigine as «similar» to the opioid combination.

What comes next

Chronic pain is already being studied, and this is the most interesting direction. In painful diabetic neuropathy three phase 3 trials are running and one phase 2 trial is complete. There are programmes in painful lumbosacral radiculopathy and in small fibre disease.

If the effect holds up in chronic neuropathic pain, the drug's significance changes in kind: today it is an alternative to an opioid for a few days after surgery; there it would be an alternative to gabapentinoids and antidepressants for months.

How to take it

Tablets are swallowed whole; the starting dose is taken on an empty stomach, an hour before food or two hours after, otherwise onset is delayed.

  • This is medicine for days, not for continuous use. All available efficacy data were gathered over 48 hours.
  • Where it is sold. The drug is prescription-only and sold in the US; no registration could be found in the European Union, the United Kingdom or Ukraine.

Who should see a doctor first

This is a prescription drug, and its warnings section is not a formality.

  • One contraindication, and it matters: strong CYP3A inhibitors. Concomitant use is prohibited because they raise exposure to the drug and its active metabolite.
  • Avoid grapefruit throughout treatment, for the same reason.
  • Liver. In severe hepatic impairment (Child-Pugh class C) use should be avoided; in moderate impairment (class B) the dose is lower.
  • Hormonal contraception. The drug is itself a CYP3A inducer. If the contraceptive contains a progestin other than levonorgestrel or norethindrone, an additional non-hormonal method is needed during treatment and for 28 days after it.
  • Common adverse reactions, more frequent than on placebo: pruritus, muscle spasms, raised creatine phosphokinase, rash.
  • Pregnancy. There are no data on use in pregnancy. In rat studies, effects on implantation and maintenance of pregnancy occurred at doses from 2.2 times the maximum recommended human dose.
  • The indication is limited to acute pain in adults. Safety and effectiveness have not been established in children.
  • If it is offered to you for chronic pain, that is off-label prescribing, and the conversation with your doctor should start there.

On the heart, separately: at twice the exposure of the maximum recommended dose, no clinically significant QT prolongation was observed.

Bottom line

Suzetrigine is a genuine event in pain pharmacology: for the first time in decades pain relief has taken a fundamentally different route — not through the brain, but by switching off the signal in the nerve itself. Against placebo the drug works; that is shown in two phase 3 trials.

That route has a chance of delivering what opioids cannot — relief that does not reinforce itself. And studies in chronic pain are already under way.

Source: Suzetrigine (Journavx): The First Non-Opioid Painkiller of a New Class in Decades — universum.earth. Dr. Pereligyn.

Come back
Request a call back